Nautilus Biotechnology, Inc. NAUT

Company Overview

Nautilus Biotechnology, Inc. is a life sciences and biotechnology company focused on advancing proteomics, the large-scale study of proteins, to enable a more comprehensive understanding of human biology and disease. The company is developing an integrated technology platform designed to measure and analyze the human proteome at unprecedented scale and depth, with applications across biomedical research, drug discovery, and diagnostics. Nautilus primarily serves pharmaceutical companies, biotechnology firms, and academic and translational research institutions.

The company’s core value proposition centers on its ability to analyze billions of proteins simultaneously using a single-molecule, array-based approach that combines proprietary hardware, reagents, and software. Nautilus positions itself as seeking to overcome limitations of traditional mass spectrometry–based proteomics by offering higher throughput, scalability, and consistency. Founded in 2013, Nautilus evolved from an early-stage research venture into a publicly traded company following its merger with a special purpose acquisition company in 2021, after which it began trading on Nasdaq under the ticker NAUT.